SCHEMBL5598708

SCHEMBL5598708

CCOC(=O)CC(C)c1cccc(C(C)C)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
GABRA1 P14867 2/20 0.52
GABRB1 P18505 2/20 0.52
FAAH O00519 1/20 0.52
LMNA P02545 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
HPGD P15428 1/20 0.52
GABRG2 P18507 1/20 0.52
PTGS1 P23219 1/20 0.52
SLC6A2 P23975 1/20 0.52
HTR2C P28335 1/20 0.52
GABRB3 P28472 1/20 0.52
GABRA5 P31644 1/20 0.52
GABRA3 P34903 1/20 0.52
HTR2B P41595 1/20 0.52
GABRA2 P47869 1/20 0.52
GABRB2 P47870 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5599080 0.88 FAAH (0.49) TSHRCA1CA2GABRA1GABRB1
SCHEMBL28739302 0.84 GABRA1 (0.55) TSHRCA1CA2GABRA1GABRB1
SCHEMBL27618808 0.84 NLRP3 (0.42) TSHRLMNACYP1A2CYP3A4HPGD
SCHEMBL28866732 0.81 TSHR (0.58) TSHRCA1CA2GABRA1HPGD
SCHEMBL5598897 0.80 CA1 (0.57) TSHRCA1CA2GABRA1GABRB1
Urethane SCHEMBL27800059 0.79 TSHR (0.49) TSHRCA1CA2GABRA1GABRB1
SCHEMBL27536950 0.79 CA12 (0.45) TSHRCA1CA2HIF1ANLRP3
SCHEMBL13572960 0.77 CASP1 (0.54) TSHRLMNACYP1A2CYP3A4NLRP3
SCHEMBL15968923 0.77 POLB (0.48) TSHRLMNAHPGDNLRP3MAPK1
SCHEMBL8435913 0.77 NLRP3 (0.45) TSHRNLRP3ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7226946-B2 Substituted phenol compounds useful for anesthesia and sedation THERAVANCE, INC. (US) 2007-06-05 US disclosed
US-20050032753-A1 Substituted phenol compounds useful for anesthesia and sedation THERAVANCE BIOPHARMA R&D IP, LLC 2005-02-10 US disclosed
US-6815555-B2 CONTAINING AN ESTER, ANHYDRIDE, PHOSPHONATE OR THIOESTER GROUP THERAVANCE, INC. 2004-11-09 US disclosed
EP-1430017-A2 SUBSTITUTED PHENOL COMPOUNDS USEFUL FOR ANESTHESIA AND SEDATION Theravance, Inc. (US) 2004-06-23 EP disclosed
US-20030119790-A1 Substituted phenol compounds useful for anesthesia and sedation THERAVANCE BIOPHARMA R&D IP, LLC 2003-06-26 US disclosed
WO-2003026632-A2 SUBSTITUTED PHENOL COMPOUNDS USEFUL FOR ANESTHESIA AND SEDATION THERAVANCE, INC. (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032753-A1 Substituted phenol compounds useful for anesthesia and sedation OPRL1, PNMT, PPARG TSHR 2222/4885CA1 1352/4885CA2 820/4885
US-20030119790-A1 Substituted phenol compounds useful for anesthesia and sedation OPRL1, PNMT, PPARG TSHR 2222/4885CA1 1352/4885CA2 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.